


Click [here](#) if you are having trouble viewing this message.



## Working together to accelerate patient access to advanced therapies

The Advanced Therapy Treatment Centre (ATTC) Network aims to develop robust systems for the routine delivery of ATMPs as a standard of care throughout the NHS in the United Kingdom.

The three centres; [Innovate Manchester Advanced Therapy Centre Hub](#) (iMATCH), [Midlands-Wales Advanced Therapy Treatment Centre](#) (MW-ATTC, comprising Birmingham, Wales and Nottingham) and [Northern Alliance Advanced Therapies Treatment Centre](#) (NA-ATTC, comprising Scotland, Newcastle and Leeds) are working together with industry partners and the public sector to develop the necessary processes, skilled staff and infrastructure at scale as more treatments move from clinical trial to marketed products.

This month we are pleased to summarise some key news from the network. For further information visit the [network website](#).

---

## CGT Catapult news



INDUSTRIAL  
STRATEGY

UK Research  
and Innovation



**European Union**

European Regional  
Development Fund

### **Construction completed on expansion phase of CGT Catapult manufacturing centre**

Completion builds on the success of first six clean rooms which have seen exceptional demand. The manufacturing centre's additional 6 modules will continue to accelerate the growth of the industry in the UK.

[Read the press release](#)



### **Cell and Gene Therapy Catapult CEO to Retire**

Keith Thompson, Chief Executive Officer of the Cell and Gene Therapy Catapult will be retiring in April 2020 after eight years in the role. Keith has led the company to make a strong impact on building the cell and gene therapy ecosystem both in the UK and internationally.

[Read the announcement](#)

## ATTC news



### **NA-ATTC assesses the readiness of hospitals to deliver ATMPs**

A questionnaire is being used by NA-ATTC's NHS partners to benchmark their Institutional Readiness for exemplar Advanced Therapies to help identify and address any gaps that may impact these hospitals' ability to deliver such innovative medicines.

[Find out more](#)

### **Workshop: Optimising the design of clinical trials for advanced therapies**

The event consisted of talks, panel discussions and a breakout session to present multiple aspects of the design and execution clinical trials in this complex landscape. To find out the major messages from the day visit the website.

[Find out more](#)



### **iMatch partners expand capabilities to support the delivery of clinical trials**

Aptus Clinical are now able to offer a full Clinical Data Management service, including eCRF Design, EDC Build, Medical Coding to Data Cleaning and Laboratory Management. In addition, Datatrial and Aptus Clinical have co-developed an electronic trial master file (eTMF) system to provide a cost-effective and efficient solution for use in early phase clinical trials.

[Find out more](#)



### **MW-ATTC opens first trial in Cardiff**

The Rexgenero study (REX-001-004/005) is one of the first exemplar products in the field of advanced therapies to emerge from the MW-ATTC network. The study is looking at the efficacy and safety of intra-arterial administration of REX-001 to those patients with critical limb ischaemia and diabetes in treating ischaemic rest pain or ischaemic ulceration.

[Find out more](#)

## **Learn from CGT Catapult**

### **Cell and Gene Meeting on the Mesa**

*2 - 4 October 2019, Carlsbad, CA*

Cell and Gene Therapy Catapult will be attending this conference and taking part in the following sessions:

Keith Thompson, Chief Executive Officer  
Customized Solutions for Genetic Medicines – Navigating the GMP Supplier Landscape  
Wednesday 2nd October, 7.15-8.45am

Dr Jacqueline Barry, Chief Clinical Officer

Fireside chat: Brexit's effect on cell and gene therapy regulation  
Wednesday 2nd October, 10:45–11:15am

#### [More information](#)

#### **Safety of Stem-Cell Derived Therapies: Trends and Future Technologies**

*7-8 October 2019, Edinburgh, UK*

Jacqueline Barry  
Safe Starting Materials for Stem Cell-Derived Therapies  
09.30-10.40am, Day 1

Michaela Sharpe  
Pre-Clinical Safety Considerations  
13.30-15.15, Day 1

Poster presentation: Beata Surmacz-Cordle  
Safety of Cell Therapy Products: In vitro Methods to Assess the Tumorigenicity of Human Cell-Based Therapeutic Products

#### **UK Bioscience Forum 2019**

*17 October 2019, London, UK*

Chief Manufacturing Officer Dr Stephen Ward will be taking part in a panel discussion on **Future Skills for UK BioIndustry**.



Share this email on social media

---

## Contact us

+44 (0) 203 728 9500

12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT



The Cell and Gene Therapy Catapult takes your data very seriously, you can read how we may use it in our [privacy policy](#). If you no longer want to hear from us [unsubscribe here](#).